A multicenter, randomized trial of daily high-dose interferon-alfa 2b for the treatment of chronic hepatitis C: Pretreatment stratification by viral burden and genotype

American Journal of Gastroenterology

Volumn 95, Issue 11, 2000, Pages 3225-3229

  Fried, Michael W ^{a,b,c,d,e,f,g,h,i}   Shiffman, Mitchell ^{a,b,c,d,e,f,g,h}   Sterling, Richard K ^{a,b,c,d,e,f,g,h}   Weinstein, Jeffrey ^{a,b,c,d,e,f,g,h}   Crippin, Jeffrey ^{a,b,c,d,e,f,g,h}   Garcia, Gabriel ^{a,b,c,d,e,f,g,h}   Wright, Teresa L ^{a,b,c,d,e,f,g,h}   Conjeevaram, Hari ^{a,b,c,d,e,f,g,h}   Reddy, K Rajender ^{a,b,c,d,e,f,g,h}   Peter, Joy ^{a,b,c,d,e,f,g,h}   Cotsonis, George A ^{a,b,c,d,e,f,g,h}   Nolte, Frederick S ^{a,b,c,d,e,f,g,h}  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

^d BAYLOR UNIVERSITY   (United States)

^e STANFORD UNIVERSITY   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g UNIVERSITY OF CHICAGO   (United States)

^h UNIVERSITY OF MIAMI   (United States)

ⁱ UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT ALPHA2A INTERFERON; RIBAVIRIN;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG MEGADOSE; FEMALE; GENOTYPE; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VIRUS GENOME; VIRUS LOAD;

ADULT; ANTIVIRAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; MALE; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, VIRAL; VIRAL LOAD;

EID: 0033756124     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9270(00)02226-7     Document Type: Article

References (22)

1. Significance of serum hepatitis C virus RNA levels in chronic hepatitis C
2. Genotypes and titers of hepatitis C virus for predicting response to interferon in patients with chronic hepatitis C
3. Pretreatment hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent predictors of sustained response to interferon alfa therapy in chronic hepatitis C
4. Factors predictive of response to interferon-a therapy in hepatitis C virus infection
5. Combination therapy with interferon plus ribavirin for the initial treatment of chronic hepatitis C
6. Clinical application of hepatitis C virus genotyping and quantitation
7. Efficacy of interferon alfa therapy depends primarily on hepatitis C virus RNA level
8. A prospective randomized trial comparing lymphoblastoid to recombinant interferon alfa 2a as therapy for chronic hepatitis C
9. Raising the dose of interferon does not improve the response in chronic hepatitis C
10. An escalating dose regimen of recombinant interferon alfa-2a in the treatment of chronic hepatitis C
11. Response to higher dose of interferon alfa-2b in patients with chronic hepatitis C: A randomized multicenter trial
12. Evaluation of two methods for quantitation of hepatitis C virus RNA
13. Clinical characterization of a competitive PCR assay for quantitative testing of hepatitis C virus
14. Comparison of plasma viral loads among individuals infected with hepatitis C virus genotypes 1, 2, and 3 by Quantiplex HCV RNA versions 1 and 2, Roche Monitor assay, and in-house limiting dilution method
15. National Institutes of Health Consensus Development Panel Statement
16. Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa therapy
17. Treatment of chronic hepatitis C with consensus interferon: A multicenter randomized controlled trial
18. Interferon alfa 2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C
19. Randomised trial of interferon alfa 2b and ribavirin for 48 weeks or 24 weeks versus interferon alfa 2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus
20. Factors predictive of response to interferon-alfa therapy in hepatitis C virus infection
21. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C
22. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon alpha therapy